Takayuki Ota

Takayuki Ota

Auto-generated profile, based on publicly available information

Takayuki Ota

Johnson & Johnson, La Jolla, California, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MOMiyo Ota
Miyo Ota
KHKenneth B. Hoehn
Kenneth B. Hoehn
TOTakayuki Ota
Takayuki Ota
CACarlos José Aranda
Carlos José Aranda
SFSara Friedman
Sara Friedman
MLMaria Alicia Curotto de Lafaille
Maria Alicia Curotto de Lafaille
Food allergy is caused by allergen-specific IgE antibodies but little is known about the B cell memory of persistent IgE responses. Here we describe in human pediatric peanut allergy CD23 + IgG1 + memory B cells arising in type 2 responses that contain peanut specific clones and generate IgE cells on activation. These ‘type2-marked’ IgG1 + memory B cells differentially express IL-4/IL-13 regulated genes FCER2 / CD23, IL4R , and germline IGHE and carry highly mutated B cell receptors (BCRs). Further, high affinity memory B cells specific for the main peanut allergen Ara h 2 mapped to the population of ‘type2-marked’ IgG1 + memory B cells and included convergent BCRs across different individuals. Our findings indicate that CD23 + IgG1 + memory B cells transcribing germline IGHE are a unique memory population containing precursors of pathogenic IgE. One-Sentence Summary: We describe a unique population of IgG + memory B cells poised to switch to IgE that contains high affinity allergen-specific clones in peanut allergy.

22 December 2025 in JCI Insight
Verified
Journal Article
Open access
DSDavid Strawn
David Strawn
JKJames G. Krueger
James G. Krueger
RBRobert Bissonnette
Robert Bissonnette
KEKilian Eyerich
Kilian Eyerich
LFLaura K. Ferris
Laura K. Ferris
AKArun K. Kannan
Arun K. Kannan
BACKGROUND: Icotrokinra is the first and only targeted oral peptide that selectively binds the IL-23 receptor with high affinity to precisely inhibit IL-23 signaling. Icotrokinra demonstrated high rates of complete skin clearance and durable disease control in the phase IIb trial, FRONTIER-1, and its long-term extension, FRONTIER-2, in participants with moderate-to-severe plaque psoriasis. This study evaluated systemic and skin pharmacodynamic response of icotrokinra and its relationship to clinical response in FRONTIER participants. METHODS: FRONTIER-1 participants received icotrokinra or placebo for 16 weeks. FRONTIER-2 followed participants for up to 1 year of treatment; placebo participants transitioned to icotrokinra after week 16. Systemic pharmacodynamic changes were assessed in serum through week 52. Skin pharmacodynamic changes were assessed using transcriptomic analysis of skin biopsies and protein quantification in tape-strip samples through week 16. RESULTS: Icotrokinra dose-dependently reduced serum levels of the IL-23/IL-17 axis and psoriasis disease biomarkers through week 52, with maximal reductions observed with the highest 100 mg twice-daily dose. Proteomic analyses showed icotrokinra selectively blocked IL-23–driven inflammation without broader impacts on circulating proteins, including serum IL-23 levels. Sixteen weeks of icotrokinra, but not placebo, reduced expression of psoriasis-associated genes in lesional skin. Icotrokinra treatment also reduced psoriasis-relevant proteins in week 16 lesional skin tape-strips to levels comparable to nonlesional samples. CONCLUSION: Icotrokinra induced a dose-dependent pharmacodynamic response, with early (week 4) and sustained (week 52) reductions in biomarkers of IL-23 pathway activation and psoriasis disease severity, which correlated with clinical response. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05223868, NCT05364554. FUNDING: Johnson & Johnson.

30 August 2024 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
ESEric L. Simpson
Eric L. Simpson
EGEmma Guttman-Yassky
Emma Guttman-Yassky
JPJeffrey Pawlikowski
Jeffrey Pawlikowski
EGEric G. Ghorayeb
Eric G. Ghorayeb
TOTakayuki Ota
Takayuki Ota
MLMark Lebwohl
Mark Lebwohl
Bermekimab is a human-derived recombinant monoclonal antibody that exhibits immunoregulatory activity by specifically blocking interleukin-1α activity. Four phase 2 studies evaluated efficacy and safety of bermekimab in patients with moderate-to-severe atopic dermatitis (AD). In addition, a novel human skin explant model was developed to assess bermekimab pharmacokinetics/pharmacodynamics and proteomic/transcriptomic effects. Study 1 (NCT03496974, N = 38) was an open-label, dose escalation study of subcutaneous bermekimab (200 mg or 400 mg). Study 2 (NCT04021862, N = 87) was a double-blind, placebo-controlled, randomized (1:1:1) study of subcutaneous bermekimab (400 mg every week (qw) or every 2 weeks) or placebo. GENESIS (NCT04791319, N = 198) was a double-blind, placebo- and active-comparator-controlled, randomized (1:1:2:2) study of placebo, subcutaneous bermekimab (350 mg or 700 mg qw), or dupilumab. LUNA (NCT04990440, N = 6) was a double-blind, placebo-controlled, randomized (4:1) study of intravenous bermekimab 800 mg qw or placebo. A novel human ex vivo skin pharmacodynamic assay supported phase 0 (NCT03953196) and phase 1 (NCT04544813) studies. In Study 1, 400 mg subcutaneous bermekimab showed improvement in efficacy assessments (e.g., ≥ 75% improvement of EASI over baseline, IGA 0/1, and worst itch); however, efficacy was not confirmed in Study 2 or GENESIS. Consequently, GENESIS and LUNA were terminated early. The novel human ex vivo skin pharmacodynamic assay demonstrated that bermekimab reduced downstream skin injury responses. Although bermekimab showed potential as an AD treatment in preclinical and early open-label trials, larger controlled studies (Study 2 and GENESIS) did not confirm those initial results.

25 August 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
SFSeth Forman
Seth Forman
LKLea Kephart
Lea Kephart
TOTakayuki Ota
Takayuki Ota
JPJeff Pawlikowski
Jeff Pawlikowski
JJJingzhi Jiang
Jingzhi Jiang
AKAlexa B. Kimball
Alexa B. Kimball